News

In 2013, BIO and ViS launched this initiative to improve the efficiency of clinical development for pediatric therapeutics. BIO and its member companies work with ViS to use

The Phase III clinical trial data from the ongoing HPV 070 (NCT01381575) study show that immunogenicity of two doses of Cervarix given at months 0 and 12 is

Oxford, which is focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, secured the rights under its existing strategic collaboration with Amgen. The

Dravet Syndrome is also known as Severe Myoclonic Epilepsy of Infancy (SMEI), a rare and catastrophic treatment-resistant form of childhood epilepsy. Following confirmation from FDA, the company intends

As part of the deal, Bayer will acquire Merck’s existing OTC business, including the global trademark and prescription rights for Claritin and Afrin. Merck has also entered into

CMC Biologics global chief operations officer Gustavo Mahler said the company looks forward to working with MacroGenics to further develop and advance this immuno-oncology program. "This contract highlights

The new inhibitors will be developed against an Eternygen target to treat metabolic diseases using Evotec’s technology platform and broad expertise in drug discovery and pre-clinical development. Currently,

Under the deal, each company has made a $1m investment in CET, which is majority owned by Cumberland and partners with academic research centers to develop promising biopharmaceutical

The sNDA application was granted Priority Review designation with a stated FDA Prescription Drug User Fee Act (PDUFA) review date of 18 September 2014. Currently, XTANDI is approved